微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 46.51% | 0.16% | 0.97% | 81/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 46.06% | -1.54% | -2.4% | 86/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 47.2% | -5.45% | 5.53% | 77/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 44.72% | 2.58% | -3.69% | 90/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 46.43% | 0.99% | -0.75% | 84/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 46.79% | 5.87% | -6.26% | 84/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 49.91% | 13.95% | 14.49% | 77/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 43.6% | 37.62% | -5.18% | 97/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 45.98% | 57.43% | 4.04% | 90/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 44.19% | 67.53% | 0.89% | 95/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 43.8% | 65.72% | 38.28% | 94/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 31.68% | -17.08% | 8.46% | 119/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 29.21% | -33.14% | 10.71% | 118/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 26.38% | -38.44% | -0.2% | 129/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 26.43% | -37.78% | -30.81% | 123/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 38.2% | -0.92% | -12.54% | 109/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 43.68% | 15.14% | 1.94% | 83/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 42.85% | 21.64% | 0.87% | 90/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 42.48% | 17.88% | 10.18% | 80/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 38.56% | 8.97% | 1.64% | 109/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 37.94% | 7.37% | 7.68% | 93/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 35.23% | -0.71% | -2.24% | 108/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.04% | -0.22% | 1.85% | 89/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 35.39% | -5.43% | 0.14% | 109/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 35.34% | -2.1% | -0.42% | 88/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 35.48% | 0.89% | -1.75% | 90/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 36.12% | -16.51% | -3.47% | 83/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 37.42% | -9.21% | 3.67% | 99/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 36.09% | -5.54% | 2.62% | 80/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 35.17% | -7.74% | -18.7% | 82/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 43.26% | 16.56% | 4.96% | 65/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 41.22% | 4.8% | 7.87% | 77/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 38.21% | 0.23% | 0.23% | 64/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 38.12% | 5.07% | 2.71% | 68/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 37.12% | 6.43% | -5.63% | 58/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 39.33% | -15.63% | 3.17% | 70/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 38.12% | -21.13% | 5.07% | 48/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 36.28% | -21.73% | 4.04% | 57/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 34.87% | -19.03% | -25.19% | 52/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 46.61% | -27.11% | -3.56% | 45/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 48.34% | -24.5% | 4.27% | 31/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 46.35% | -25.89% | 7.62% | 37/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 43.07% | -30.75% | -32.65% | 37/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |